🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. TAK-583

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  2. TAK-653

    Takeda

    Treatment-Resistant Depression

    phase 2 small molecule terminated

    1 trial

  3. TAK-659

    Takeda

    AML

    phase 2 small molecule terminated

    1 trial

  4. TAK-662

    Takeda

    Congenital Protein C Deficiency

    phase 2 small molecule completed

    1 trial

  5. TAK-700

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  6. TAK-715 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  7. TAK-755

    Takeda

    Acute Ischemic Stroke

    phase 2 mab active

    1 trial

  8. TAK-783 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  9. TAK-788

    Takeda

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  10. TAK-788

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  11. TAK-850

    Takeda

    Influenza Prevention

    phase 2 small molecule terminated

    1 trial

  12. TAK-850

    Takeda

    Influenza Infection

    phase 2 mab completed

    1 trial

  13. TAK-850

    Takeda

    Influenza

    phase 2 small molecule completed

    1 trial

  14. TAK-850 0.5 mL injection

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  15. TAK-853

    Takeda

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  16. TAK-906 Maleate

    Takeda

    Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

    phase 2 small molecule completed

    1 trial

  17. TAK-906 Maleate

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  18. TAK-919

    Takeda

    Coronavirus Disease (COVID-19)

    phase 2 mab completed

    1 trial

  19. TAK-931

    Takeda

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  20. TAK-935

    Takeda

    Developmental and/or Epileptic Encephalopathies

    phase 2 small molecule completed

    1 trial

  21. TAK-935

    Takeda

    Epilepsy

    phase 2 small molecule completed

    2 trials

  22. TAK-951

    Takeda

    Postoperative Nausea and Vomiting (PONV)

    phase 2 small molecule completed

    1 trial

  23. TAK-954

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  24. TAK-954

    Takeda

    Critical Illness

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources